PCOS Has a New Name: Here's What That Means for Your Care.
Last Updated: July 2026
Medically reviewed by Dr. Kelli Peiffer, owner and founder of West Side Concierge Medicine
For years, women with polycystic ovary syndrome have navigated a diagnosis that didn't quite add up. The name pointed to the ovaries. The symptoms pointed everywhere else: irregular periods, weight that can be difficult to manage despite consistent effort, acne that persisted well past adolescence, hair where it wasn't wanted (and thinning where it was), fatigue, anxiety, blood sugar instability, cardiovascular risk–symptoms that most primary care visits never surfaced at all. Women left appointments with a diagnosis that explained one piece of the picture and sent them back into a system that treated each remaining symptom as a separate problem belonging to a different specialist.
That experience now has a more accurate clinical name. On May 12, 2026, a global consortium of researchers and patient advocates published a landmark paper in The Lancet formally renaming polycystic ovary syndrome as polyendocrine metabolic ovarian syndrome, or PMOS. The name change followed more than a decade of research and advocacy, more than 14,000 survey responses from patients and clinicians across every world region, and consensus across 56 patient and professional organizations. It is the largest initiative ever undertaken to rename a medical condition.
The old name was not just imprecise. It was, in a measurable way, harmful.
Why the Name Mattered More Than It Seemed
The term polycystic ovary syndrome implied the presence of pathological ovarian cysts, which are not actually a feature of the condition. Research confirms that the ovaries in PMOS do not develop the kind of abnormal cysts the name implies. What actually occurs is a collection of small, growth-arrested follicles, a real and clinically significant finding, just not the pathological cysts the old name suggested. What does define the condition is a complex network of endocrine and metabolic dysfunction that extends well beyond the ovaries.
That mismatch had real consequences. The inaccurate name contributed to delayed diagnosis, fragmented care, and stigma, while curtailing research and policy alignment. When a condition is perceived as an ovarian or gynecologic problem, medical education, research funding, clinical guidelines, and treatment protocols all follow that framing. Women with PCOS were often seen primarily in ob-gyn or reproductive medicine contexts, even when their most urgent health concerns were metabolic, cardiovascular, or psychological.
Medical students often learned about the condition only in gynecology courses, despite it being an endocrine condition that affects many body systems. The result was a generation of clinicians who understood PCOS as a fertility problem, not as the chronic, multisystem condition it actually is.
Up to 70% of affected individuals remained undiagnosed. Those who did receive a diagnosis frequently reported dissatisfaction with the information and care they received. The name itself had become an obstacle.
What PMOS Actually Describes
Polyendocrine metabolic ovarian syndrome affects one in eight women. It is characterized by hormonal fluctuations with impacts on weight, metabolic health, mental health, skin, and the reproductive system. Each word in the new name carries clinical weight.
Polyendocrine reflects that the condition involves multiple interacting hormonal systems, not a single organ. PMOS encompasses multiple interacting endocrine abnormalities rather than an isolated ovarian disorder. Hyperandrogenism is a defining endocrine and diagnostic feature, with elevated ovarian and often adrenal androgens contributing to hirsutism, acne, alopecia, and metabolic features. Central neuroendocrine abnormalities include increased gonadotropin-releasing hormone pulsatility, with consequent elevations in luteinizing hormone.
Metabolic reflects a dimension of the condition that has been systematically undertreated. Insulin resistance affects the majority of people with PMOS, with studies estimating prevalence between 50 and 70% of those diagnosed, and potentially higher among lean women when more sensitive testing methods are used. It contributes to androgen excess. Cardiometabolic complications including impaired glucose tolerance, gestational diabetes, type 2 diabetes, dyslipidemia, hypertension, and vascular dysfunction are increased in PMOS and contribute to cardiovascular disease risk.
Ovarian remains in the name because ovarian dysfunction is real and central to the condition. Neuroendocrine abnormalities disrupt ovarian steroidogenesis and impair follicular maturation, resulting in ovulatory dysfunction, menstrual irregularity, and infertility. But the ovaries are one part of a much larger picture, not the whole of it.
The psychological dimension is worth naming explicitly even though it did not make it into the acronym. Depression, anxiety, disordered eating, and poor quality of life are documented features of PMOS, understood now as downstream consequences of the endocrine disruption at the condition's core.
What Changes, and What Doesn't
The rename is not a new diagnosis. If you were diagnosed with PCOS, that diagnosis still applies. The clinical criteria for identifying the condition remain the same. What changes is the framework through which care is delivered, researched, and understood.
A planned transition period is underway, supported by a co-designed global implementation strategy, with full integration into international clinical guidelines expected in the coming years. In the meantime, you will likely encounter both names in clinical settings, insurance documentation, and lab reports. That is expected. The science has moved; the paperwork will follow.
What this shift does, immediately and meaningfully, is reframe the conversation your provider should be having with you. PMOS is not a fertility condition that some women also happen to have. It is a chronic, multisystem hormonal and metabolic condition that requires longitudinal care across several clinical domains: hormones, metabolic function, cardiovascular risk, bone health, mental health, and more. Women who have been managed only for one or two of those domains have not received complete care for this condition.
The Case for Care That Reflects the Whole Condition
The name PMOS describes what this condition is. What it demands, in terms of clinical management, is a provider who understands it across all of its dimensions and has the time and structure to address them.
That is not a realistic ask of a fifteen-minute primary care visit. It is exactly what the concierge model is designed to make possible.
Ms.Medicine affiliate providers are trained in evidence-based women's health and practice within a membership structure that allows for the kind of thorough, ongoing clinical relationship this condition requires. For women with a PMOS diagnosis, or who suspect they may have one, the work is not finding a separate specialist for each symptom cluster. The work is finding a primary care provider who sees the whole picture and has the time to act on it.
If you have lived with a PCOS diagnosis and have felt that your care has never quite addressed what you were actually experiencing, that is worth revisiting with a provider trained to look at the full clinical landscape. The science now agrees with you.
Additional Resources
The Lancet. Diabetes & Endocrinology. 2022. Joham AE, Norman RJ, Stener-Victorin E, et al.Review
The Cochrane Database of Systematic Reviews. 2019. Sharpe A, Morley LC, Tang T, Norman RJ, Balen AH.SR
The Cochrane Database of Systematic Reviews. 2021. Zhang J, Tang L, Kong L, et al.SR
EClinicalMedicine. 2025. Teede HJ, Moran LJ, Morman R, et al.
Human Reproduction. 2023. Teede HJ, Tay CT, Laven J, et al.Guideline
Clinical Endocrinology. 2019. Zhang D, Yang X, Li J, Yu J, Wu X.RCT
7. Insulin Resistance and Polycystic Ovary Syndrome.
Current Pharmaceutical Design. 2016. Moghetti P.Review
Human Reproduction. 2013. Stepto NK, Cassar S, Joham AE, et al.Clinical Trial
9. Prevalence of Polycystic Ovary Syndrome: A Global and Regional Systematic Review and Meta-Analysis.
Human Reproduction Update. 2026. Neven ACH, Forslund M, Ranasinha S, et al.NewSR
10. ACOG Practice Bulletin No. 194: Polycystic Ovary Syndrome.
Obstetrics and Gynecology. 2018. Committee on Practice Bulletins—GynecologyGuideline
